Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells

Santos, Mark F.; Mannam, Venkat K.R.; Craft, Barbara S.; Puneky, Louis V.; Sheehan, Natale T.; Lewis, Robert E.; Cruse, Julius M.

doi:10.1016/j.yexmp.2014.04.001

Cited by 50 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inhibition of NK cell signalling leads to tumour lysis through cytolytic granules release and apoptosis induction. These effects of the NK cells are decreased in CTC positive patients with metastatic colon, breast and other types, compared to CTC negative patients [138][139][140][141].…”

Section: Immune Surveillancementioning

confidence: 90%

Vascular related pathologies in cardiovascular disease and cancer

Ananthaseshan

Religa

2018

hpc

View full text Add to dashboard Cite

Authors' contribution Wkład autorów: A. Study design/planning zaplanowanie badań B. Data collection/entry zebranie danych C. Data analysis/statistics dane-analiza i statystyki D. Data interpretation interpretacja danych E. Preparation of manuscript przygotowanie artykułu F. Literature analysis/search wyszukiwanie i analiza literatury G. Funds collection zebranie funduszy Summary Cancer and Cardiovascular diseases (CVD) are the two most prominent causes of death worldwide. Emerging evidence indicates shared risk factors and a common biology between these diseases. For instance, chronic inflammation has a significant role in contributing to both diseases. An alteration of the vasculature and the endothelial cells plays a key role in pathogenesis of CVD and cancer. The widespread overlap regarding disease prevention and risk factors for these diseases suggest a common mechanism in terms of molecular pathways. The goal of this tutorial is to present common problems and mechanism of these two mayor diseases.

show abstract

Section: Immune Surveillancementioning

confidence: 90%

Vascular related pathologies in cardiovascular disease and cancer

Ananthaseshan

Religa

2018

hpc

View full text Add to dashboard Cite

show abstract

“…CTCs can modulate NK cell anti-tumor activity through production of inhibitory cytokines (e.g., IL-1β, IL-8, IL-10, and prostaglandin E2) that block the NK cell immunoglobulin receptors (KIRs) [2,3] (Figure 3a). Toll-like receptors (TLRs), which are expressed on macrophages and dendritic cells (DCs), can activate NK cell cytolytic killing [67]. The increase of CTC number in metastatic cancers is associated with TLR down-regulation and NK cell activity inhibition [67].…”

Section: Ctcs Escape the Innate Immune System Responsementioning

confidence: 99%

“…Toll-like receptors (TLRs), which are expressed on macrophages and dendritic cells (DCs), can activate NK cell cytolytic killing [67]. The increase of CTC number in metastatic cancers is associated with TLR down-regulation and NK cell activity inhibition [67]. Moreover, CTCs also reduce the therapeutic efficacy of adoptive transfer of autologous NK cells after chemotherapy [62].…”

Section: Ctcs Escape the Innate Immune System Responsementioning

confidence: 99%

“…The high shear forces in lung capillaries induce micro-particle production by CTCs. Following their uptake and ingestion, macrophages are activated and contribute to metastatic lesion initiation and development [67]. In physiological conditions, CD47 (the 'do not eat me' signal) at the leukocyte surface binds to signal-regulatory protein α (SIRPα), its ligand on macrophages and DCs, inhibiting leukocyte phagocytosis [73].…”

Section: Ctcs Escape the Innate Immune System Responsementioning

confidence: 99%

See 1 more Smart Citation

The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance

Dianat‐Moghadam

Azizi

Eslami-S

et al. 2020

Cancers

View full text Add to dashboard Cite

Metastases and cancer recurrence are the main causes of cancer death. Circulating Tumor Cells (CTCs) and disseminated tumor cells are the drivers of cancer cell dissemination. The assessment of CTCs’ clinical role in early metastasis prediction, diagnosis, and treatment requires more information about their biology, their roles in cancer dormancy, and immune evasion as well as in therapy resistance. Indeed, CTC functional and biochemical phenotypes have been only partially characterized using murine metastasis models and liquid biopsy in human patients. CTC detection, characterization, and enumeration represent a promising tool for tailoring the management of each patient with cancer. The comprehensive understanding of CTCs will provide more opportunities to determine their clinical utility. This review provides much-needed insights into this dynamic field of translational cancer research.

show abstract

“…Also, it has been reported that ≈60% CRC patients will go on to suffer from tumor metastasis [2]. Importantly, studies have indicated a high prevalence of mortality, recurrence and metastasis of CRC to be associated with immunocompromised patients [3, 4]. One epidemiologic survey showed low activity of natural killer (NK) cells to be associated with an increased risk of cancer [5, 6], and that infiltration of CD8 + T cells and NK cells are closely related to the clinical outcome of CRC [7].…”

Section: Introductionmentioning

confidence: 99%

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer

Wang

Wei

Fang

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of epidermal growth factor receptor. This antibody is widely used for colorectal cancer (CRC) treatment but its influence on the immune system is incompletely understood. Methods: The immune influence of cetuximab therapy in CRC patients was investigated by analyzing peripheral blood mononuclear cells using flow cytometry. We undertook in vitro cytotoxicity and cytokine-profile assays to ascertain the immunomodulatory effect of cetuximab treatment. Results: The number of CD3⁺ T, CD8⁺ T, and natural killer (NK) cells was increased significantly and T-regulatory cells reduced gradually after cetuximab treatment. Percentage of CD4⁺ T, natural killer T (NKT)-like, invariant NKT, and dendritic cells was similar between baseline patients and cetuximab patients. Expression of CD137 on NK and CD8⁺ T cells was increased significantly after 4 weeks of cetuximab therapy. In vitro cetuximab treatment markedly increased expression of CD137 and CD107a on NK and CD8⁺ T cells. Cetuximab treatment promoted the cytotoxic activity of NK and CD8⁺ T cells against tumor cells. Conclusion: Cetuximab treatment promotes activation of the immune response but alleviates immunosuppression: this might be the underlying anti-CRC effect of cetuximab.

show abstract

Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells

Cited by 50 publications

References 31 publications

Vascular related pathologies in cardiovascular disease and cancer

Vascular related pathologies in cardiovascular disease and cancer

The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer

Contact Info

Product

Resources

About